Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CHEK2 |
Variant | V109A |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | CHEK2 V109A does not lie within any known functional domains of the Chek2 protein (UniProt.org). V109A has been identified in the scientific literature (PMID: 21765476), but has not been biochemically characterized and therefore, its effect on Chek2 protein function is unknown (PubMed, Sep 2024). |
Associated Drug Resistance | |
Category Variants Paths |
CHEK2 mutant CHEK2 V109A |
Transcript | NM_007194.4 |
gDNA | chr22:g.28725361A>G |
cDNA | c.326T>C |
Protein | p.V109A |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_007194.4 | chr22:g.28725361A>G | c.326T>C | p.V109A | RefSeq | GRCh38/hg38 |
NM_001349956.1 | chr22:g.28725361A>G | c.326T>C | p.V109A | RefSeq | GRCh38/hg38 |
NM_007194 | chr22:g.28725361A>G | c.326T>C | p.V109A | RefSeq | GRCh38/hg38 |
NM_145862.2 | chr22:g.28725361A>G | c.326T>C | p.V109A | RefSeq | GRCh38/hg38 |
NM_145862.2 | chr22:g.28725361A>G | c.326T>C | p.V109A | RefSeq | GRCh38/hg38 |
NM_007194.3 | chr22:g.28725361A>G | c.326T>C | p.V109A | RefSeq | GRCh38/hg38 |
NM_001349956.2 | chr22:g.28725361A>G | c.326T>C | p.V109A | RefSeq | GRCh38/hg38 |
NM_145862 | chr22:g.28725361A>G | c.326T>C | p.V109A | RefSeq | GRCh38/hg38 |
XM_011529843 | chr22:g.28725361A>G | c.326T>C | p.V109A | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CHEK2 mutant | breast cancer | no benefit | Olaparib | Case Reports/Case Series | Actionable | In a Phase II trial (TBCRC 048), Lynparza (olaparib) treatment did not result in an objective response in 7 patients with metastatic breast cancer harboring only germline mutations in CHEK2 (PMID: 33119476; NCT03344965). | 33119476 |
CHEK2 mutant | Advanced Solid Tumor | no benefit | Olaparib | Phase II | Actionable | In a Phase II trial, Lynparza (olaparib) treatment did not demonstrate clinical activity in patients with advanced solid tumors harboring ATM (n=13) or CHEK2 (n=14) mutations (Ann Oncol (2023) 34 (suppl_2): S242; NCT03967938). | detail... |
CHEK2 mutant | breast cancer | not applicable | N/A | Guideline | Risk Factor | Germline CHEK2 mutations are associated with increased risk of developing breast cancer (NCCN.org). | detail... |
CHEK2 mutant | prostate cancer | not applicable | N/A | Guideline | Risk Factor | Germline CHEK2 mutations are associated with increased risk of developing prostate cancer (NCCN.org). | detail... |